Answers are grounded in this paper and cite their sources.
Cross-sectional study uncovers high endemic lymphogranuloma venereum rates in symptomatic rectal infections, highlighting the need for empirical three-week doxycycline therapy.
Background Lymphogranuloma venereum (LGV), caused by Chlamydia trachomatis L-genotypes, has re-emerged as a major anorectal infection in men who have sex with men (MSM), especially in people living with HIV. Distinguishing LGV from non-LGV C. trachomatis is essential because LGV requires 3 weeks of doxycycline. Long-term Latin American data are lacking. Methods Anorectal swabs from patients with suspected anorectal sexually transmitted infections were studied in a cross-sectional study conducted at two Buenos Aires coloproctology referral centers (August 2017–November 2025). Anorectal swabs were tested for C. trachomatis by NAAT and positive samples were genotyped by PCR-RFLP targeting ompA . Monthly LGV positivity was analyzed using the modified Farrington algorithm to detect epidemic peaks and seasonality, with sensitivity analysis excluding months with <7 samples. Results Of 700 anorectal swabs, 285 (41%) were C. trachomatis positive. Among public-hospital samples with conclusive genotyping, 148/179 (83%) were LGV; in the private center, 78 additional LGV cases were confirmed, totaling 226 LGV cases. HIV coinfection was 78% in LGV versus 100% in non-LGV cases ( p = 0.0016). Concurrent T. pallidum or N. gonorrhoeae infection occurred in 25% of cases and was associated with LGV. The endemic baseline was approximately 32% (range 28–36%), with no seasonal pattern or trend. Pandemic-era epidemic alarms disappeared after excluding low-volume months. Conclusions Anorectal LGV is endemic in Buenos Aires, with no seasonality, and a ∼32% pre-test probability among symptomatic patients at specialized clinics. This supports considering empirical 3-week doxycycline for MSM with rectal symptoms and C. trachomatis infection when genotyping is unavailable, until further trials confirm the non-inferiority of proposed shortened regimens. Biovar-specific testing remains the goal for targeted therapy.
No takes yet. Share an insight, caveat, or question.
López et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: